Amicus Therapeutics, Inc. (LON:0HF9)
London · Delayed Price · Currency is GBP · Price in USD 6.10
-0.21 (-3.33%)
At close: Jul 31, 2025
Amicus Therapeutics Company Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease.
It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold.
Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Amicus Therapeutics, Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 499 |
| CEO | Bradley Campbell |
Contact Details
Address: 47 Hulfish Street Princeton, Delaware 08542 United States | |
| Phone | 609 662 2000 |
| Website | amicusrx.com |
Stock Details
| Ticker Symbol | 0HF9 |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US03152W1099 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bradley Campbell | Chief Executive Officer |
| Simon Nicolas Harford | Chief Financial Officer |
| Andrew Faughnan | Head of Investor Relations |